title: How I treat type 2 variant forms of von Willebrand disease.
abstract: Type 2 von Willebrand disease (VWD) includes a wide range of qualitative abnormalities of von Willebrand factor structure and function resulting in a variable bleeding tendency. According to the current classification, 4 different subtypes can be identified, each with distinctive phenotypic and therapeutic characteristics. Current available laboratory methods allow a straightforward approach to VWD subtyping, and although the precise molecular characterization remains complex, it is not required for appropriate treatment of the vast majority of cases. Desmopressin can be useful only in a few type 2 cases compared with patients with actual quantitative deficiency (type 1), most often in variants with a nearly normal multimeric pattern (type 2M). However, since no laboratory test accurately predicts response to desmopressin, a trial test should always be performed in all type 2 VWD patients, with the exception of type 2B ones. Replacement therapy with plasma-derived von Willebrand factor-factor VIII concentrates represents the safe mainstay of treatment of all patients, particularly those not responding to desmopressin or requiring a sustained hemostatic correction because of major surgery or bleeding. A significant patient bleeding history correlates with increased bleeding risk and should be considered in tailoring the optimal antihemorrhagic prophylaxis in the individual patient.
authors.affiliation: Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy; and.
authors.forename: Alberto
authors.identifier: http://orcid.org/0000-0002-0119-5204
authors.initials: A
authors.lastname: Tosetto
authors.affiliation: Center for Bleeding Disorders, Department of Heart and Vessels, Careggi University Hospital, Florence, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Castaman
mesh_terms: D000328:Adult; D000368:Aged; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D004338:Drug Combinations; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy; D006487:Hemostasis / Q000187:drug effects; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D056728:von Willebrand Disease, Type 2 / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D014841:von Willebrand Factor / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D006490:Hemostatics; C509423:factor VIII, von Willebrand factor drug combination; D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin